Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA

Neoplasia (United States)

Volumn 16, Issue 1, 2014, Pages 97-103

  Martignetti, John A ^a   Camacho Vanegas, Olga ^a   Priedigkeit, Nolan ^a   Camacho, Catalina ^a   Pereira, Elena ^a   Lin, Li ^a   Garnar Wortzel, Leopold ^a   Miller, Dagny ^a   Losic, Bojan ^a   Shah, Hardik ^a   Liao, Jun ^a   Ma, Jian ^b   Lahiri, Pratik ^b   Chee, Mark ^c   Schadt, Eric ^a   Dottino, Peter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b University of Illinois at Urbana Champaign   (United States)

^c Prognosys Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CIRCULATING TUMOR DNA; COMPLEMENTARY DNA; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG MONITORING; GENE EXPRESSION; GENE FUSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MTT ASSAY; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RNA EXTRACTION; RNA ISOLATION; RNA SEQUENCE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84900410805     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131900     Document Type: Article

References (16)

1. Bidard FC, Weigelt B, and Reis-Filho JS (2013). Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 5, 207ps14.
2. Mandel P and Métais P (1948). Les acides nucléiques du plasma sanguin chez l'homme. C R Acad Sci Paris 142, 241-243.
3. Koffler D, Agnello V, Winchester R, and Kunkel HG (1973). The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 52, 198-204.
4. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. (2008). Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985-990.
5. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, et al. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199-1209.
6. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, et al. (2012). Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4, 136ra68.
7. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, et al. (2013). Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112.
8. McBride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, Hämäläinen E, Stebbings LA, Andersson LC, Flanagan AM, et al. (2010). Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 49, 1062-1069.
9. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, et al. (2010). Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2, 20ra14.
10. Li Y, Chien J, Smith DI, and Ma J (2011). FusionHunter: identifying fusion transcripts in cancer using paired-end RNA-seq. Bioinformatics 27, 1708-1710.
11. Kim D and Salzberg SL (2011). TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 12(8), R72.
12. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, Griffith M, Heravi Moussavi A, Senz J, Melnyk N, et al. (2011). deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7, e1001138.
13. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, et al. (2013). Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 3, 636-647.
14. Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, and Bischoff FZ (2006). Quantification of total plasma cell-free DNA in ovarian cancer using realtime PCR. Ann NY Acad Sci 1075, 230-234.
15. Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615.
16. Bast RC Jr (2010). Commentary: CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 116, 2850-2853.